Skip to contentB
Bioxytran, Inc
B
BIXTBioxytran, Inc Q2 2019 · 10-Q
Revenue—
Net Income-$130.29K-$130.29Kno prior Q2 2018 on file EPS Diluted$0.00$0.00no prior Q2 2018 on file Operating Income-$106,498— Operating Cash Flowderived-$73,652—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bioxytran, Inc · CIK 1445815 · Engraved from SEC EDGAR
ended Jun 30, 2019 · filed Aug 9, 2019 · 40 d after period end